Relypsa to Present at Two Upcoming Investor Conferences in March

REDWOOD CITY, Calif., Feb. 26, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq: RLYP), a biopharmaceutical company, today announced that John Orwin, Chief Executive Officer, will present a corporate overview of the company at the Cowen & Co. 34th Annual Health Care Conference in Boston, MA on March 4 at 10:40 am ET and at the 26th Annual ROTH Conference in Dana Point, CA on March 10 at 5:00 pm PT.

To access the live webcasts and subsequent archived recordings of these presentations, please visit Relypsa's website at www.relypsa.com.

About Relypsa, Inc.

Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The Company's two-part pivotal Phase 3 trial of its lead product candidate, patiromer, for the treatment of hyperkalemia, a life-threatening condition defined as abnormally elevated levels of potassium in the blood, has been completed and the primary and secondary endpoints were met. Relypsa has global royalty-free commercialization rights to patiromer, which has intellectual property protection in the U.S. until at least 2030. More information is available at www.relypsa.com.

CONTACT: Relypsa, Inc.

         Shari Annes, IR and Corporate Communications
         [email protected], 650-888-0902

You May Also Be Interested In

• VEON and JazzWorld Acquire TPL Insurance to Expand Digital Insurance Access Across Pakistan
• Virtour Media Expands Real Estate Photography Services in Ventura
• Data Center Robotics Market to Reach USD 113,432.96 Million by 2035 Amid Hyperscale Expansion and AI-Driven Operations - DC Market Insights